{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:54Z","timestamp":1790115834867,"version":"4.0.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.autrev.2025.103889","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:04:30Z","timestamp":1753286670000},"page":"103889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular risk in psoriatic arthritis: How can we manage it?"],"prefix":"10.1016","volume":"24","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Alciati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103889_bb0005","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0010","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","article-title":"Multimorbidity and comorbidity in psoriatic arthritis - a perspective","volume":"16","author":"Lubrano","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103889_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20976975","article-title":"Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus","volume":"12","author":"Fragoulis","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0020","article-title":"Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs?","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2025.103889_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/acr.20363","article-title":"Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4081\/reumatismo.2011.148","article-title":"Cardiovascular involvement in psoriatic arthritis","volume":"63","author":"Atzeni","year":"2011","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2025.103889_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2025.103889_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review","volume":"27","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2025.103889_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a Meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0055","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/key286","article-title":"Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study","volume":"58","author":"Charlton","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103889_bb0065","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3899\/jrheum.160070","article-title":"Disease activity and increased risk of cardiovascular death among patients with psoriatic arthritis","volume":"43","author":"Juneblad","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0070","first-page":"877","article-title":"Subclinical atherosclerosis in psoriatic arthritis: a case-control study","volume":"35","author":"Eder","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0075","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.24014","article-title":"Subclinical carotid atherosclerosis in patients with psoriatic arthritis","volume":"59","author":"Tam","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-016-1074-2","article-title":"Husni ME the impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis","volume":"18","author":"Lucke","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103889_bb0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/art.40389","article-title":"Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity","volume":"70","author":"Szentpetery","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0090","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.22884","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semarthrit.2006.09.001","article-title":"Prevalence and rosk factors of atherosclerosis in patients with psoriatic arthritis","volume":"36","author":"Kimhi","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/ATVBAHA.110.214585","article-title":"CaRRDs study group carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-\u03b1 blockers and traditional disease-modifying antirheumatic drugs","volume":"31","author":"Di Minno","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2025.103889_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10067-011-1892-1","article-title":"Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study","volume":"31","author":"Costa","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0110","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/rheumatology\/kes213","article-title":"Increase in ventricular arterial stiffness in patients with psoriatic arthritis","volume":"51","author":"Shang","year":"2012","journal-title":"Rheumatol Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.22530","article-title":"Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez- Juanatey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/1756-185X.12336","article-title":"Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery","volume":"19","author":"Sharma","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0125","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/acr.22536","article-title":"Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study","volume":"67","author":"Ernste","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103889_bb0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41584-024-01149-x","article-title":"Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases","volume":"20","author":"Buch","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0150","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/ard.2005.050963","article-title":"Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment","volume":"65","author":"van Kuijk","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0155","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","article-title":"Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis","volume":"43","author":"Danning","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0036-1584918","article-title":"Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function","volume":"25","author":"Garg","year":"2016","journal-title":"Int J Angiol"},{"key":"10.1016\/j.autrev.2025.103889_bb0165","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/art.40499","article-title":"Correlation of high-density lipoprotein-associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease","volume":"70","author":"Husni","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0170","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and Meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-022-00049-1","article-title":"The why and how of adaptive immune responses in ischemic cardiovascular disease","volume":"1","author":"Mallat","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u201cpsoriatic march\u201d: a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0195","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.22185","article-title":"Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis","volume":"66","author":"Labitigan","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103889_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/met.2009.0124","article-title":"Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis","volume":"8","author":"Raychaudhuri","year":"2010","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.autrev.2025.103889_bb0205","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.5888\/pcd14.160287","article-title":"Metabolic syndrome prevalence by race\/ethnicity and sex in the United States, National Health and nutrition examination survey, 1988-2012","volume":"14","author":"Moore","year":"2017","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016400","article-title":"Obesity in psoriatic arthritis: comparative prevalence and associated factors","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2025.103889_bb0215","first-page":"9","article-title":"Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated","author":"Raadsen","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103889_bb0220","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s10067-020-05132-1","article-title":"Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing","volume":"39","author":"Su","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0225","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0230","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","article-title":"Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation","volume":"47","author":"Tam","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103889_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.autrev.2025.103889_bb0240","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0245","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semarthrit.2008.06.001","article-title":"Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease","volume":"39","author":"Gonzalez-Gay","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0260","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/1756-185X.13553","article-title":"Systematic review of depression and anxiety in psoriatic arthritis","volume":"22","author":"Kamalaraj","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjmed.2023.04.036","article-title":"Association of depression and cardiovascular disease","volume":"136","author":"Krittanawong","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0270","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1176\/appi.ajp.2009.09060881","article-title":"Association of Western and traditional diets with depression and anxiety in women","volume":"167","author":"Jacka","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.autrev.2025.103889_bb0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PSY.0b013e31820ad12b","article-title":"Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research","volume":"73","author":"Stetler","year":"2011","journal-title":"Psychosom Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0280","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00006842-199901000-00010","article-title":"Cardiac autonomic control buffers blood pressure variability responses to challenge: a psychophysiologic model of coronary artery disease","volume":"61","author":"Sloan","year":"1999","journal-title":"Psychosom Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2025.103889_bb0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0018-506X(02)00016-8","article-title":"Neuroendocrine aspects of hypercortisolism in major depression","volume":"43","author":"Parker","year":"2003","journal-title":"Horm Behav"},{"key":"10.1016\/j.autrev.2025.103889_bb0295","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0300","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1038\/s41380-020-00867-4","article-title":"The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression","volume":"26","author":"Mac Giollabhui","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.autrev.2025.103889_bb0305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/01.ATV.0000079512.66448.1D","article-title":"C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study","volume":"23","author":"Luc","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2025.103889_bb0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.reuma.2010.03.003","article-title":"Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics","volume":"7","author":"Freire","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.autrev.2025.103889_bb0315","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0320","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/art.40695","article-title":"Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis","volume":"71","author":"Cheng","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0325","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1093\/rheumatology\/keaa025","article-title":"Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?","volume":"59","author":"Cheng","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103889_bb0330","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2020-217595","article-title":"DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study","volume":"79","author":"Lam","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0335","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.autrev.2025.103889_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0345","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0350","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0355","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and Meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2025.103889_bb0360","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2018.6992","article-title":"Cardiovascular effects of methotrexate in immunemediated inflammatory diseases (review)","author":"B\u0103l\u0103nescu","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0365","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1038\/s41598-021-87766-y","article-title":"The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study","volume":"11","author":"Hong","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103889_bb0370","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/17512433.2021.1932461","article-title":"Methotrexate and cardiovascular risk in rheumatic diseases: a comprehensive review","volume":"14","author":"Verhoeven","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103889_bb0375","first-page":"11","article-title":"Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: a pilot study","author":"Dehpouri","year":"2019","journal-title":"Dermatol Reports"},{"key":"10.1016\/j.autrev.2025.103889_bb0380","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis","volume":"19","author":"Deyab","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103889_bb0385","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/138161282004140213123852","article-title":"Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review","volume":"20","author":"Brezinski","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2025.103889_bb0390","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/art.22447","article-title":"Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study","volume":"56","author":"Sattar","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0400","first-page":"8","article-title":"Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis","author":"Baoqi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0405","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.biopha.2018.07.110","article-title":"The pleiotropic role of interleukin-17 in atherosclerosis","volume":"106","author":"Allam","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2025.103889_bb0410","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"27","author":"Tzellos","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2025.103889_bb0415","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody Ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0420","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0425","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2025.103889_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004591","article-title":"Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study","volume":"22","author":"Lin","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0435","first-page":"100","article-title":"Loukeri E effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2025.103889_bb0440","doi-asserted-by":"crossref","unstructured":"Barbarroja N, L\u00f3pez-Medina C, Escudero-Contreras A, Arias-de la Rosa I. Clinical and Molecular Insights Into Cardiovascular Disease in Psoriatic Patients and the Potential Protective Role of Apremilast. doi:https:\/\/doi.org\/10.3389\/fimmu.2024.1459185.","DOI":"10.3389\/fimmu.2024.1459185"},{"key":"10.1016\/j.autrev.2025.103889_bb0445","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0450","first-page":"678","article-title":"Cardiometabolic effects of apremilast in patients with psoriatic arthritis: a prospective cohort study","volume":"52","author":"Hansildaar","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102902","article-title":"JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103889_bb0460","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0465","unstructured":"European Medicines Agency. Janus Kinase Inhibitors (JAKi)\u2014Referral; 2023. Https:\/\/WwwEmaEuropaEu\/En\/Medicines\/Human\/Referrals\/Jan Us-Kinase-Inhibitors-Jaki n.d."},{"key":"10.1016\/j.autrev.2025.103889_bb0470","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0475","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clinthera.2025.01.005","article-title":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis","volume":"47","author":"Zhao","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2025.103889_bb0480","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0485","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2014-206824","article-title":"On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Tr\u00f8ndelag health study","volume":"75","author":"Gulati","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0490","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/rheumatology\/kead610","article-title":"The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the clinical practice research datalink","volume":"63","author":"Hughes","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103889_bb0495","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3899\/jrheum.170025","article-title":"Underestimation of risk of carotid subclinical atherosclerosis by cardiovascular risk scores in patients with psoriatic arthritis","volume":"45","author":"Shen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0500","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10067-021-06002-0","article-title":"Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients","volume":"41","author":"Galarza-Delgado","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0505","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jbspin.2017.07.002","article-title":"Is the SCORE chart underestimating the real cardiovascular (CV) risk of patients with psoriatic arthritis? Prevalence of subclinical CV disease detected by carotid ultrasound","volume":"85","author":"Mart\u00ednez-Vidal","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2025.103889_bb0510","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/art.42694","article-title":"Derivation and internal validation of a disease-specific cardiovascular risk prediction model for patients with psoriatic arthritis and psoriasis","volume":"76","author":"Colaco","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0515","first-page":"10","article-title":"Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period","author":"Polo","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103889_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152694","article-title":"Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases","volume":"72","author":"Llorca","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103889_bb0525","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3899\/jrheum.100893","article-title":"Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis","volume":"38","author":"Atzeni","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0530","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/07853890.2015.1031822","article-title":"Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies","volume":"47","author":"Di Minno","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0535","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3899\/jrheum.190729","article-title":"Disease activity influences cardiovascular risk reclassification based on carotid ultrasound in patients with psoriatic arthritis","volume":"47","author":"Palmou-Fontana","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0540","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3899\/jrheum.181223","article-title":"Role of carotid ultrasound and systematic coronary risk evaluation charts for the cardiovascular risk stratification of patients with psoriatic arthritis","volume":"47","author":"Mart\u00ednez-Vidal","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00296-016-3617-x","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound","volume":"37","author":"Ib\u00e1\u00f1ez-Bosch","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103889_bb0550","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-Centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2025.103889_bb0555","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3899\/jrheum.160053","article-title":"Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis","volume":"43","author":"Ikdahl","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0560","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/03009742.2021.1920169","article-title":"Degree of arterial stiffness is comparable across inflammatory joint disease entities","volume":"51","author":"F\u00f6hse","year":"2022","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103889_bb0565","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004309","article-title":"Artificial intelligence in rheumatology research: what is it good for?","volume":"11","author":"Sequ\u00ed-Sabater","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103889_bb0570","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s10067-025-07418-8","article-title":"AI in psoriatic disease (\u201cPsAI\u201d): current insights and future directions","volume":"44","author":"Venerito","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103889_bb0575","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X251343579","article-title":"Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis","volume":"17","author":"Bilgin","year":"2025","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2025.103889_bb0580","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez677","article-title":"A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis","volume":"59","author":"Navarini","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103889_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102660","article-title":"Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review","volume":"73","author":"Singh","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2025.103889_bb0590","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00296-023-05415-1","article-title":"Artificial intelligence-based preventive, personalized and precision medicine for cardiovascular disease\/stroke risk assessment in rheumatoid arthritis patients: a narrative review","volume":"43","author":"Al-Maini","year":"2023","journal-title":"Rheumatol Int"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:51:39Z","timestamp":1763769099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1568997225001491"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103889","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk in psoriatic arthritis: How can we manage it?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103889"}}